Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity
 
  • Details

Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity

Journal
BMC Medicine
Journal Volume
11
Journal Issue
1
Pages
106
Date Issued
2013
Author(s)
Hsu Y.-C.
Chen H.-Y.
Yuan S.
SUNG-LIANG YU  
Lin C.-H.
Wu G.
PAN-CHYR YANG  
Li K.-C.
DOI
10.1186/1741-7015-11-106
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-84876091266&doi=10.1186%2f1741-7015-11-106&partnerID=40&md5=73ea2ca4986f12bc345d4c453fda17c4
https://scholars.lib.ntu.edu.tw/handle/123456789/523567
Abstract
Background: Chemosensitivity and tumor metastasis are two primary issues in cancer management. Cancer cells often exhibit a wide range of sensitivity to anti-cancer compounds. To gain insight on the genetic mechanism of drug sensitivity, one powerful approach is to employ the panel of 60 human cancer cell lines developed by the National Cancer Institute (NCI). Cancer cells also show a broad range of invasion ability. However, a genome-wide portrait on the contributing molecular factors to invasion heterogeneity is lacking.Methods: Our lab performed an invasion assay on the NCI-60 panel. We identified invasion-associated (IA) genes by correlating our invasion profiling data with the Affymetrix gene expression data on NCI-60. We then employed the recently released chemosensitivity data of 99 anti-cancer drugs of known mechanism to investigate the gene-drug correlation, focusing on the IA genes. Afterwards, we collected data from four independent drug-testing experiments to validate our findings on compound response prediction. Finally, we obtained published clinical and molecular data from two recent adjuvant chemotherapy cohorts, one on lung cancer and one on breast cancer, to test the performance of our gene signature for patient outcome prediction.Results: First, we found 633 IA genes from the invasion-gene expression correlation study. Then, for each of the 99 drugs, we obtained a subset of IA genes whose expression levels correlated with drug-sensitivity profiles. We identified a set of eight genes (EGFR, ITGA3, MYLK, RAI14, AHNAK, GLS, IL32 and NNMT) showing significant gene-drug correlation with paclitaxel, docetaxel, erlotinib, everolimus and dasatinib. This eight-gene signature (derived from NCI-60) for chemosensitivity prediction was validated by a total of 107 independent drug tests on 78 tumor cell lines, most of which were outside of the NCI-60 panel. The eight-gene signature predicted relapse-free survival for the lung and breast cancer patients (log-rank P = 0.0263; 0.00021). Multivariate Cox regression yielded a hazard ratio of our signature of 5.33 (95% CI = 1.76 to 16.1) and 1.81 (95% CI = 1.19 to 2.76) respectively. The eight-gene signature features the cancer hallmark epidermal growth factor receptor (EGFR) and genes involved in cell adhesion, migration, invasion, tumor growth and progression.Conclusions: Our study sheds light on the intricate three-way interplay among gene expression, invasion and compound-sensitivity. We report the finding of a unique signature that predicts chemotherapy survival for both lung and breast cancer. Augmenting the NCI-60 model with in vitro characterization of important phenotype-like invasion potential is a cost-effective approach to power the genomic chemosensitivity analysis. ? 2013 Hsu et al.; licensee BioMed Central Ltd.
SDGs

[SDGs]SDG3

Other Subjects
actin; alpha actin; CD44v antigen; dasatinib; docetaxel; epidermal growth factor receptor; erlotinib; everolimus; focal adhesion kinase; Janus kinase 1; myosin; myosin light chain kinase; paclitaxel; Smad1 protein; Smad3 protein; transforming growth factor beta2; vinculin; antineoplastic agent; tumor marker; antineoplastic agent; tumor marker; actin filament; adjuvant chemotherapy; article; breast cancer; cancer cell; cell adhesion; cell migration; chemosensitivity; controlled study; drug mechanism; drug response; drug screening; female; gene expression; genetic association; human; human cell; lung cancer; major clinical study; male; outcome assessment; prediction; tumor growth; tumor invasion; aged; biosynthesis; cell proliferation; gene expression profiling; genetics; metastasis; microarray analysis; middle aged; Neoplasms; pathology; prognosis; survival; very elderly; biosynthesis; neoplasm; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Proliferation; Female; Gene Expression Profiling; Humans; Male; Microarray Analysis; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Survival Analysis; Tumor Markers, Biological; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Proliferation; Female; Gene Expression Profiling; Humans; Male; Microarray Analysis; Middle Aged; Neoplasm Metastasis; Neoplasms; Prognosis; Survival Analysis; Tumor Markers, Biological
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science